NEWS RELEASE


FEATURE: Clinical Development Partnerships

2012-05-31 12:53:53

Clinical Development Partnerships (CDP) is a joint initiative between CRT and Cancer Research UK. Targeting leading biotechnology and pharmaceutical companies with large pipelines that are forced to prioritise the agents taken into clinical development; its sole purpose is to bring life to de-prioritised cancer agents. It offers early clinical development with no upfront cost to the company and projects are undertaken on a shared-risk basis.

CDP will fund each study through early stage development with the company being given the first option to take forward and commercialise the drug in exchange for future royalty payments to CRT. If the company elects not to progress the project, all rights will be given to CRT to secure an alternative development partner, thus ensuring the programme has every possible chance of reaching patients.

Since its formation, 7 agents have been adopted under this initiative's innovative business model including AstraZeneca, Astex Therapeutics, GlaxoSmithKline, Merck Serono and Immatics with 2 projects well advanced in Phase I and a further due to enter the clinic shortly. 

The CDP team are actively seeking new agents to bring into the portfolio with a focus on small molecules and monoclonal antibodies.

To find out more, arrange a meeting with Victoria John, Head of Clinical Partnerships (vjohn@cancertechnology.com) or Ian Walker, Head of Alliances (iwalker@cancertechnology.com) at the forthcoming BIO Conference in Boston 18-21st June.

Notes to editors